
Historically, scientists have only been able to leverage structure-based drug design (SBDD) when high-resolution crystal or cryo-EM structures are available for receptors of interest. This paradigm appeared to be shifting with the release of AlphaFold2, a machine learning-based algorithm purported to be capable of accurately predicting the structure of nearly every protein target in the